US 5871753A
· Crabtree et al.
· 1999
[cited by applicant]
US 5910573A
· Pluckthun et al.
· 1999
[cited by applicant]
US 6291158B1
· Winter et al.
· 2001
[cited by applicant]
US 6291161B1
· Lerner et al.
· 2001
[cited by applicant]
US 6423498B1
· Markland et al.
· 2002
[cited by applicant]
US 6649595B2
· Clackson et al.
· 2003
[cited by applicant]
US 6972193B1
· Crabtree et al.
· 2005
[cited by applicant]
US 9587020B2
· Wu et al.
· 2017
[cited by applicant]
US 20120100160A1
· Lucas et al.
· 2012
[cited by applicant]
US 20160017302A1
· Dotti et al.
· 2016
[cited by applicant]
US 20170081411A1
· Engels
· 2017
[cited by examiner]
US 20200071399A1
· Jarjour et al.
· 2020
[cited by applicant]
US 20210236546A1
· Jarjour et al.
· 2021
[cited by applicant]
US 20230031838A1
· Jarjour et al.
· 2023
[cited by applicant]
US 20230287111A1
· Jarjour et al.
· 2023
[cited by applicant]
CN 109311963A
· 2019
[cited by applicant]
JP 2002503667A
· 2002
[cited by applicant]
JP 2002508971A
· 2002
[cited by applicant]
JP 2016531567A
· 2016
[cited by applicant]
JP 2017522879A
· 2017
[cited by applicant]
WO WO1999036553A2
· 1999
[cited by applicant]
WO WO1999041258A1
· 1999
[cited by applicant]
WO WO2006072620A1
· 2006
[cited by applicant]
WO WO2006095164A1
· 2006
[cited by applicant]
WO WO2007098934A1
· 2007
[cited by applicant]
WO WO2012082841A2
· 2012
[cited by applicant]
WO 2014051433A1
· 2014
[cited by applicant]
WO WO2014127261A1
· 2014
[cited by applicant]
WO 2014138306A1
· 2014
[cited by applicant]
WO WO2015017214A1
· 2015
[cited by applicant]
WO 2015142661A1
· 2015
[cited by applicant]
WO WO2015150771A1
· 2015
[cited by applicant]
WO 2016014535A1
· 2016
[cited by applicant]
WO WO2016014553A1
· 2016
[cited by applicant]
WO 2017027392A1
· 2017
[cited by applicant]
WO 2017125897A1
· 2017
[cited by applicant]
WO WO2017180993A1
· 2017
[cited by applicant]
WO 2018026953A1
· 2018
[cited by applicant]
WO 2018102795A2
· 2018
[cited by applicant]
WO WO2018127585A1
· 2018
[cited by applicant]
WO 2018144535A1
· 2018
[cited by applicant]
WO WO2019118885A1
· 2019
[cited by applicant]
WO WO2019118895A1
· 2019
[cited by applicant]
WO 2019188885A1
· 2019
[cited by applicant]
WO 2020052543A1
· 2020
[cited by applicant]
WO 2020113063A1
· 2020
[cited by applicant]
WO 2020123938A1
· 2020
[cited by applicant]
WO WO2020123933A1
· 2020
[cited by applicant]
WO WO2020123936A1
· 2020
[cited by applicant]
WO WO2020123947A1
· 2020
[cited by applicant]
WO 2020147708A1
· 2020
[cited by applicant]
WO 2020193767A1
· 2020
[cited by applicant]
WO 2020227073A1
· 2020
[cited by applicant]
WO WO2020227475A1
· 2020
[cited by applicant]
WO WO2020227481A1
· 2020
[cited by applicant]
WO 2021016585A1
· 2021
[cited by applicant]
WO 2021050948A1
· 2021
[cited by applicant]
WO WO2021067347A1
· 2021
[cited by applicant]
WO WO2021207613A1
· 2021
[cited by applicant]
Leclerc, M., et al., 2016. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood, The Journal of the American Society of Hematology, 128(12), pp. 1651-…
[cited by examiner]
Abate-Daga et al., CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. May 18, 2016;3:16014.
[cited by applicant]
Alder et al., Antibody responses of variable lymphocyte receptors in the lamprey. Nat Immunol. Mar. 2008;9(3):319-27.
[cited by applicant]
Banaszynski et al., Characterization of the FKBP⋅Rapamycin⋅FRB Ternary Complex. J Am Chem Soc. 2005;127(13):4715-4721.
[cited by applicant]
Baral et al., Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. May 2006;12(5):580-4.
[cited by applicant]
Barthelemy et al., Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem. Feb. 8, 2008;283(6):3639-3654.
[cited by applicant]
Bayle et al., Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol. Jan. 2006;13(1):99-107.
[cited by applicant]
Beavil et al., Alpha-helical coiled-coil stalks in the low-affinity receptor for IgE (Fc epsilon RII/CD23) and related C-type lectins. Proc Natl Acad Sci U S A. Jan. 15, 1992;89(2):753-7.
[cited by applicant]
Belshaw et al., Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A. May 14, 1996;93(10):4604-7.
[cited by applicant]
Beste et al., Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A. Mar. 2, 1999;96(5):1898-903.
[cited by applicant]
Binz et al., Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol. Sep. 12, 2003;332(2):489-503.
[cited by applicant]
Binz et al., Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol. Oct. 2005;23(10):1257-68.
[cited by applicant]
Brentjens et al., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. Mar. 20, 2013;5(177):177ra38.
[cited by applicant]
Brentjens et al., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. Nov. 3, 2011;118(18):4817-28.
[cited by applicant]
Brown et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. Jun. 30, 1994;369(6483):756-8.
[cited by applicant]
Capon et al., Designing CD4 immunoadhesins for AIDS therapy. Nature. Feb. 9, 1989;337(6207):525-31.
[cited by applicant]
Carpenito et al., Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. Mar. 3, 2009;106(9):3360-5.
[cited by applicant]
Challita et al., Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. Feb. 1995;69(2)…
[cited by applicant]
Cortez-Retamozo et al., Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. Apr. 15, 2004;64(8):2853-7.
[cited by applicant]
Craik et al., Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol. Dec. 17, 1999;294(5):1327-36.
[cited by applicant]
Curran et al., Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. Jun. 2012;14(6):405-15.
[cited by applicant]
Donnelly et al., The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol. May 2001;82(Pt 5):1027-1041.
[cited by applicant]
Dotti et al., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. Jan. 2014;257(1):107-26.
[cited by applicant]
Duong et al., Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. Jan. 2011;3(1):33-48.
[cited by applicant]
Fegan et al., Chemically controlled protein assembly: techniques and applications. Chem Rev. Jun. 9, 2010;110(6):3315-36.
[cited by applicant]
Ghahroudi et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. Sep. 15, 1997;414(3):521-6.
[cited by applicant]
Grunberg et al., Building blocks for protein interaction devices. Nucleic Acids Res. May 2010;38(8):2645-62.
[cited by applicant]
Grupp et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. Apr. 18, 2013;368(16):1509-1518.
[cited by applicant]
Hackel et al., Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol. Sep. 19, 2008;381(5):1238-52.
[cited by applicant]
Hamers-Casterman et al., Naturally occurring antibodies devoid of light chains. Nature. Jun. 3, 1993;363(6428):446-8.
[cited by applicant]
Herrin et al., Structure and specificity of lamprey monoclonal antibodies. Proc Natl Acad Sci USA. Feb. 12, 2008;105(6):2040-5.
[cited by applicant]
Hoet et al., Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol. Mar. 2005;23(3):344-8.
[cited by applicant]
Hsu et al., Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol. Dec. 1, 2005;175(1…
[cited by applicant]
Hu et al., Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. Jul. 1, 1996;56(13):3055-61.
[cited by applicant]
Huang et al., Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure. May 2005;13(5):755-68.
[cited by applicant]
Irion et al., Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol. Dec. 2007;25(12):1477-82.
[cited by applicant]
Janeway et al., Immunobiology: The Immune System in Health and Disease, 4th Edition. Current Biology Publications. pp. 148, 149 and 172, (1999).
[cited by applicant]
Jespers et al., Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. Sep. 2004;22(9):1161-5.
[cited by applicant]
June et al., T-cell therapy at the threshold. Nat Biotechnol. Jul. 10, 2012;30(7):611-4.
[cited by applicant]
Kalos et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. Aug. 10, 2011;3(95):95ra73.
[cited by applicant]
Kay, Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J. Mar. 1, 1996;314(Pt 2)(Pt 2):361-85.
[cited by applicant]
Klemm et al., Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol. 1998;16:569-92.
[cited by applicant]
Kochenderfer et al., B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. Mar. 22, 2012;119(12):2709…
[cited by applicant]
Kochenderfer et al., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. May 2013;10(5):267-76.
[cited by applicant]
Kowolik et al., D28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. Nov. 15, 2006;66(22):10995-…
[cited by applicant]
Lee et al., Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci U S A. Feb. 28, 2012;109(9):3299-304.
[cited by applicant]
Leung et al., Small Molecule-Regulated Antigen Recognition System for Inducible T Cell Targeting of CAncer Cells. Mol Ther. 2016;24:S110, Abstract No. 277.
[cited by applicant]
Main et al., Design of stable alpha-helical arrays from an idealized TPR motif. Structure. May 2003;11(5):497-508.
[cited by applicant]
Manzke et al., CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors. Int J Cancer. Aug. 27, 1999;82(5):700-8.
[cited by applicant]
Martin et al., Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol. Jan. 2003;21(1):71-6.
[cited by applicant]
Milone et al., Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. Aug. 2009;17(8):1453-64.
[cited by applicant]
Nguyen et al., Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics. Apr. 2002;54(1):39-47.
[cited by applicant]
Nguyen et al., The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J Mol Biol. Jan. 23, 1998;275(3):413-8.
[cited by applicant]
Nord et al., A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. Jun. 1995;8(6):601-8.
[cited by applicant]
Nord et al., Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. Aug. 1997;15(8):772-7.
[cited by applicant]
Nord et al., Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem. Aug. 2001;268(15):4269-77.
[cited by applicant]
Parker et al., Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel. Sep. 2005;18(…
[cited by applicant]
Pule et al., A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. Nov. 2005;12(5):933-41.
[cited by applicant]
Quintarelli et al., Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. Oct. 15, 2007;110(8):2793-802.
[cited by applicant]
Restifo et al., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. Mar. 22, 2012;12(4):269-81.
[cited by applicant]
Richards et al., Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J Mol Biol. Mar. 7, 2003;326(5):1475-88.
[cited by applicant]
Roux et al., Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci U S A. Sep. 29, 1998;95(20):11804-9.
[cited by applicant]
Ryan et al., Virus-encoded proteinases of the picornavirus super-group. J Gen Virol. Apr. 1997;78(Pt 4):699-723.
[cited by applicant]
Sato et al., Genes encoding putative natural killer cell C-type lectin receptors in teleostean fishes. Proc Natl Acad Sci U S A. Jun. 24, 2003;100(13):7779-84.
[cited by applicant]
Schlessinger, Cell signaling by receptor tyrosine kinases. Cell. Oct. 13, 2000;103(2):211-25.
[cited by applicant]
Schonfeld et al., An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A. May 19, 2009;106(20):8198-203.
[cited by applicant]
Skerra, Alternative binding proteins: anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. Jun. 2008;275(11):2677-83.
[cited by applicant]
Spencer et al., Controlling signal transduction with synthetic ligands. Science. Nov. 12, 1993;262(5136):1019-24.
[cited by applicant]
Standaert et al., Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature. Aug. 16, 1990;346(6285):671-4.
[cited by applicant]
Stephan et al., T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. Dec. 2007;13(12):1440-9.
[cited by applicant]
Stumpp et al., Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J Mol Biol. Sep. 12, 2003;332(2):471-87.
[cited by applicant]
Tal et al., An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget. Nov. 15, 2014;5(21):10949-58.
[cited by applicant]
Till et al., CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. Apr. 26, 2012;119(17):3940-50.
[cited by applicant]
Varadamsetty et al., Designed Armadillo repeat proteins: library generation, characterization and selection of peptide binders with high specificity. J Mol Biol. Nov. 23, 2012;424(1-2):68-87.
[cited by applicant]
Vincke et al., General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. Jan. 30, 2009;284(5):3273-3284.
[cited by applicant]
Vita et al., Scorpion toxins as natural scaffolds for protein engineering. Proc Natl Acad Sci U S A. Jul. 3, 1995;92(14):6404-8.
[cited by applicant]
Weisel et al., A model for fibrinogen: domains and sequence. Science. Dec. 20, 1985;230(4732):1388-91.
[cited by applicant]
White et al., Comparison of the glycosyl-phosphatidylinositol cleavage/attachment site between mammalian cells and parasitic protozoa. J Cell Sci. Feb. 2000;113 ( Pt 4):721-7.
[cited by applicant]
Wilkie et al., Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. Oct. 2012;32(5):1059-70.
[cited by applicant]
Zelensky et al., The C-type lectin-like domain superfamily. FEBS J. Dec. 2005;272(24):6179-217.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/066223, dated May 11, 2020, 18 pages.
[cited by applicant]
Wu et al., Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. Oct. 16, 2015;350(6258):aab4077.
[cited by applicant]
Atilla et al., Optimizing C-Type Lectin-like Molecule 1 (CLL-1) Directed Car T Cell Therapy of Acute Myeloid Leukemia Pinar Ataca Atilla. Biol Blood Marrow Transplant. 2019;25:S167-S168, Abstract 230.
[cited by applicant]
Baeuerle et al., Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. May 7, 2019;10(1):2087, with supplemental information, 25 pages.
[cited by applicant]
Bannas et al., Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. Front Immunol. Nov. 22, 2017;8:1603, 13 pages.
[cited by applicant]
Brocker et al., Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur J Immunol. Aug. 1996;26(8):1770-4.
[cited by applicant]
Dahlen et al., Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. Feb. 2018;6(1):3-17.
[cited by applicant]
Ma et al., Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. Apr. 24, 2019;12(1):41, 11 pages.
[cited by applicant]
Tashiro et al., Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. Sep. 6, 2017;25(9):2202-2213.
[cited by applicant]
U.S. Appl. No. 14/908,734, filed Jan. 29, 2016, U.S. Pat. No. 10,196,444, Issued.
[cited by applicant]
U.S. Appl. No. 14/608,098, filed Jan. 28, 2015, U.S. Pat. No. 10,428,142, Issued.
[cited by applicant]
U.S. Appl. No. 16/219,640, filed Dec. 31, 2018, U.S. Pat. No. 10,457,731, Issued.
[cited by applicant]
U.S. Appl. No. 16/540,673, filed Aug. 14, 2019, 2020-0071399, Abandoned.
[cited by applicant]
U.S. Appl. No. 16/573,254, filed Sep. 17, 2019, 2020-0071401, Published.
[cited by applicant]
U.S. Appl. No. 17/675,246, filed Feb. 18, 2022, Pending.
[cited by applicant]
U.S. Appl. No. 16/771,027, filed Jun. 9, 2020, 2021-0236546, Published.
[cited by applicant]